Palvella Therapeutics appoints Jennifer J. McDonough as SVP of Market Access and Patient Services

Reuters

Yesterday

<a href="https://laohu8.com/S/PVLA">Palvella Therapeutics</a> appoints Jennifer J. McDonough as SVP of Market Access and Patient Services

Palvella appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services.
McDonough most recently served at Krystal Biotech as Senior Vice President of Patient Access, Analytics & Operations from 2021 to 2026.
At Krystal Biotech, she supported the U.S. launch of VYJUVEK following FDA approval in 2023 and helped grow annual sales to USD 389 million by 2025.
Her prior roles include senior leadership positions at Strongbridge Biopharma, Cencora, EMD Serono, and CVS Health.
In her new role, McDonough will oversee payer engagement, patient support, specialty distribution, and access strategy for Palvella’s QTORIN programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230730PRIMZONEFULLFEED9676456) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2621777076"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621777076\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621777076?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621777076","market":"us","top_or_hot":-1,"title":"Palvella Therapeutics appoints Jennifer J. McDonough as SVP of Market Access and Patient Services","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PVLA\">Palvella Therapeutics</a> appoints Jennifer J. McDonough as SVP of Market Access and Patient Services\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Palvella appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services.\n        </li>\n<li>\n          McDonough most recently served at <a href=\"https://laohu8.com/S/KRYS\">Krystal Biotech</a> as Senior Vice President of <a href=\"https://laohu8.com/S/PASO\">Patient Access</a>, Analytics &amp; Operations from 2021 to 2026.\n        </li>\n<li>\n          At Krystal Biotech, she supported the U.S. launch of VYJUVEK following FDA approval in 2023 and helped grow annual sales to USD 389 million by 2025.\n        </li>\n<li>\n          Her prior roles include senior leadership positions at Strongbridge Biopharma, Cencora, EMD Serono, and CVS Health.\n        </li>\n<li>\n          In her new role, McDonough will oversee payer engagement, patient support, specialty distribution, and access strategy for Palvella’s QTORIN programs.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230730PRIMZONEFULLFEED9676456) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palvella Therapeutics appoints Jennifer J. McDonough as SVP of Market Access and Patient Services</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalvella Therapeutics appoints Jennifer J. McDonough as SVP of Market Access and Patient Services\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PVLA\">Palvella Therapeutics</a> appoints Jennifer J. McDonough as SVP of Market Access and Patient Services\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Palvella appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services.\n        </li>\n<li>\n          McDonough most recently served at <a href=\"https://laohu8.com/S/KRYS\">Krystal Biotech</a> as Senior Vice President of <a href=\"https://laohu8.com/S/PASO\">Patient Access</a>, Analytics &amp; Operations from 2021 to 2026.\n        </li>\n<li>\n          At Krystal Biotech, she supported the U.S. launch of VYJUVEK following FDA approval in 2023 and helped grow annual sales to USD 389 million by 2025.\n        </li>\n<li>\n          Her prior roles include senior leadership positions at Strongbridge Biopharma, Cencora, EMD Serono, and CVS Health.\n        </li>\n<li>\n          In her new role, McDonough will oversee payer engagement, patient support, specialty distribution, and access strategy for Palvella’s QTORIN programs.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230730PRIMZONEFULLFEED9676456) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL8x7vBR:1","article_id":"2621777076","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621777076","pubTimestamp":1774265483,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Palvella appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services.McDonough most recently served at Krystal Biotech as Senior Vice President of Patient Access, Analytics & Operations from 2021 to 2026.At Krystal Biotech, she supported the U.S. launch of VYJUVEK following FDA approval in 2023 and helped grow annual sales to USD 389 million by 2025.Her prior roles include senior leadership positions at Strongbridge Biopharma, Cencora, EMD Serono, and CVS Health.In her new role, McDonough will oversee payer engagement, patient support, specialty distribution, and access strategy for Palvella’s QTORIN programs.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK4084":"特种房地产投资信托","NDAQ":"纳斯达克OMX交易所","BK4529":"IDC概念","XERS":"Xeris制药","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4175":"保健护理产品经销商","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4504":"桥水持仓","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4588":"碎股","BK4550":"红杉资本持仓","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","BK4007":"制药","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","KRYS":"Krystal Biotech Inc.","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","PVLA":"Palvella Therapeutics","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","COR":"CENCORA","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4585":"ETF&股票定投概念","CVS":"西维斯健康"},"translate_title":"Palvella Therapeutics任命Jennifer J.McDonough为市场准入和患者服务高级副总裁","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PVLA":0.9,"NDAQ":0.9,"CVS":0.9,"XERS":0.9,"COR":0.9,"KRYS":0.9},"content_text":"Palvella Therapeutics appoints Jennifer J. McDonough as SVP of Market Access and Patient Services\n    \n\n\n          Palvella appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services.\n        \n\n          McDonough most recently served at Krystal Biotech as Senior Vice President of Patient Access, Analytics & Operations from 2021 to 2026.\n        \n\n          At Krystal Biotech, she supported the U.S. launch of VYJUVEK following FDA approval in 2023 and helped grow annual sales to USD 389 million by 2025.\n        \n\n          Her prior roles include senior leadership positions at Strongbridge Biopharma, Cencora, EMD Serono, and CVS Health.\n        \n\n          In her new role, McDonough will oversee payer engagement, patient support, specialty distribution, and access strategy for Palvella’s QTORIN programs.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230730PRIMZONEFULLFEED9676456) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}